A $200M Bet That Breathing Your Medicine Beats Swallowing It
Avalyn Pharma wants $200 million to prove that inhaling old lung drugs beats swallowing them. The IPO pitch is elegant, but the early clinical data leaves a big question unanswered.
Imagine you've been prescribed a pill that works pretty well but makes you nauseous, gives you diarrhea, and torches your liver enzymes. Now imagine someone says: "What if we just aimed the drug directly at your lungs instead?" That's the entire pitch behind Avalyn Pharma's upcoming IPO. And investors are apparently into it to the tune of $200 million.
The Seattle-area biotech set terms last week for an offering of 11.8 million shares priced between $16 and $18, with trading expected on the Nasdaq under the ticker AVLN the week of April 27. At the top of that range, base proceeds would hit roughly $201 million. If underwriters exercise their full option to buy an additional 1.7 million shares, the total could climb to about $210 million. Morgan Stanley, Jefferies, Evercore ISI, and Guggenheim Securities are running the books.
The implied market cap? Around $628 million for a company that hasn't sold a single dose of anything yet. Welcome to biotech.
Old Drugs, New Trick
Avalyn's big idea isn't a brand-new molecule. It's a better delivery method for drugs that already exist.
Idiopathic pulmonary fibrosis (IPF) is a brutal disease where scar tissue slowly replaces healthy lung tissue. Think of it like your lungs gradually turning into leather. Patients have two approved oral treatments: pirfenidone and nintedanib (sold as Ofev by Boehringer Ingelheim). Both slow the scarring, but neither stops it. And the side effects are rough enough that many patients quit taking them altogether.
Avalyn's approach is almost comically straightforward. Take those same drugs, reformulate them for inhalation through a specialized nebulizer, and deliver them straight to the damaged tissue. Smaller doses, fewer systemic side effects, more drug where it actually matters. It's the difference between pouring weed killer on your entire lawn versus spot-treating the dandelions.
Three Candidates, One Playbook
The pipeline has three programs, all following the same logic:
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
AP01 is inhaled pirfenidone, the lead candidate. In a completed Phase 1b study called ATLAS, the drug nearly stabilized lung function over 48 weeks with fewer side effects than the oral version. Avalyn plans to push AP01 through Phase 2b and into Phase 3 trials, with $150 million earmarked for that journey.
AP02 is inhaled nintedanib. Phase 1 trials in both healthy volunteers and IPF patients are done, and the company dosed its first patient in a Phase 2 trial called AURA back in March 2026. Preclinical data showed the inhaled version delivered equivalent drug concentrations to the lungs while dramatically cutting systemic exposure. Avalyn has set aside $90 million to advance AP02 into Phase 3.
Then there's AP03, the wild card. It combines pirfenidone and nintedanib into a single inhaled formulation. Doctors have long wanted to pair these two drugs orally, but the combined side effects make it impractical. If inhalation solves that problem, AP03 could become the first real combination therapy for IPF. It's still in preclinical testing, with a modest $10 million budget to get it into the clinic.
The Fine Print Nobody's Talking About
The pitch sounds clean, but there's a catch that deserves attention.
LucidQuest, which published a due diligence brief on the offering, noted that AP01's Phase 2b data showed good tolerability but no strong signal on forced vital capacity (FVC), the key measure of lung function. In other words, the drug was gentle on patients but didn't clearly prove it was slowing the disease better than alternatives. That makes Phase 3 less of a validation exercise and more of a "costly formulation-risk bet," as the brief put it.
There's also the nebulizer question. Oral pills are easy. You pop them with breakfast. Nebulizers require sitting down with a device for several minutes, multiple times a day. If patients find the routine burdensome, adherence could suffer, which would undermine the whole value proposition. And insurance companies could require patients to try (and fail on) cheaper oral versions before covering Avalyn's inhaled alternatives, a practice called step therapy that acts like a toll booth between patients and newer treatments.
Why Now? The IPO Window Is Wide Open
Avalyn isn't going public in a vacuum. The 2026 biotech IPO market has been quietly heating up.
Q1 2026 saw $1.7 billion in total biotech IPO proceeds, the highest quarterly figure since 2021. The median deal size hit $287.5 million, more than double Q1 2025. Three separate companies raised over $300 million each.
But the window isn't open for everyone. Investors have gotten pickier since the 2021 frenzy, favoring companies with mid-to-late-stage clinical data and strong venture backing. Preclinical-stage biotechs and cell/gene therapy companies have been largely shut out. The market wants proof before writing checks.
Avalyn checks several of those boxes. The company raised a $175 million Series C in September 2023 and a $100 million Series D in July 2025, entering 2026 with $138.5 million in cash. Its CEO, Lyn Baranowski, has a track record that reads like a respiratory biotech highlight reel: she previously helped lead Pearl Therapeutics (sold to AstraZeneca for $1.15 billion).
A Market With Room to Grow
The global IPF treatment market is currently valued at approximately $3.5 billion, with projections to reach $5.2 billion or more by the early 2030s, driven by rising diagnoses and new approvals in the pipeline. Current treatments slow the disease but don't stop it. Median survival after diagnosis sits at a grim three to five years.
Boehringer Ingelheim's nerandomilast, a new oral drug, met its Phase 3 endpoint and has NDAs submitted in the US, EU, and China, with the FDA granting priority review and a decision expected in Q4 2025. Bristol Myers Squibb is running Phase 3 trials for its own oral candidate. United Therapeutics is pushing Tyvaso, an inhaled treprostinil originally approved for pulmonary hypertension, into IPF territory with positive Phase 3 results showing meaningful improvements in lung function.
Avalyn would enter a market that's crowded with oral options but surprisingly thin on inhaled alternatives. If the company can prove that breathing these drugs works meaningfully better than swallowing them, it could carve out a significant niche. If it can't, it'll have spent hundreds of millions to create a premium-priced version of something doctors can already prescribe.
The Bottom Line
Avalyn Pharma is making a conceptually elegant bet: same drugs, smarter delivery. The science behind inhaled therapy makes intuitive sense, and the unmet need in IPF is undeniable. But "makes sense" and "works in Phase 3" are very different things, and the early clinical data hasn't exactly been a home run.
With $200 million in fresh capital and a seasoned leadership team, Avalyn has the resources and credibility to find out. The key catalyst to watch is the Phase 2b topline data from the MIST trial (AP01), expected in 2027. That readout will determine whether this IPO was a prescient bet on the future of lung disease treatment, or an expensive lesson in why reformulation isn't the same as innovation.
4 min read
The $400M Bet That AI Can Design Better Drugs Than Humans
Generate Biomedicines just raised $400 million in the largest biotech IPO since 2024, betting that AI can design better drugs than humans. With a Phase 3 asthma program, a generative biology platform, and the Moderna-incubator Flagship Pioneering behind it, this is the biggest test yet of whether AI drug design can survive public markets.
